Windsong offers a state of the art technology called NeuroQuant® to improve the early detection of Alzheimer’s disease (AD), other types of dementia, multiple sclerosis, epilepsy and traumatic brain injury. The MRI software precisely measures the brain atrophy (shrinkage) by measuring the volume of the hippocampus and other brain structures that typically deteriorate with these disorders. This information allows separation of treatable causes of dementia from progressive neurodegenerative processes without available treatment at this time.
The NeuroQuant software *from CorTechs Labs, is FDA-cleared and covered by most insurance plans for measurement of brain atrophy. The results of the exam are compared to a database of healthy people of the same age and gender.
Patients who have Mild Cognitive Impairment (MCI) and decreased hippocampal size are four times more likely to progress to AD in a few years compared to patients whose hippocampus is a normal size. The hippocampus in a healthy patient shrinks at about 1% per year, compared to about 5% per year in a person with AD. Therefore, the NeuroQuant evaluation can help provide an early warning by predicting the onset of dementia. NeuroQuant has the ability to monitor brain structure volumes over time to assess for disease progression. This also helps doctors measure the impact of their treatments and assist in identifying those patients most likely to benefit from aggressive intervention in multiple sclerosis. Unfortunately, normal-sized brain structures can’t rule out dementia. However, high-functioning patients concerned about mild, but increasing, memory loss can be reassured by results that fall in the normal range.
NeuroQuant is a registered trademark of CorTechs Labs, Inc.
NeuroQuant® MRI is available Windsong’s Williamsville and Hamburg locations.
Call 716.631.2500 for more information or to make an appointment.
To access dementia resources through the Alzheimer’s Association, please visit https://www.communityresourcefinder.org/